| Description |
BI-2493 is a non-covalent and pan KRAS inhibitor. BI-2493 inhibits the interaction of GDP-bound KRAS with SOS1 in a biochemical assay using recombinant proteins with IC50s < 11nM. BI-2493 can be used in studies about KRAS-driven cancers.
|
| In Vitro |
BI-2493 inhibits the proliferation with IC50 values < 140 nM in Ba/F3 cell lines made dependent on KRAS by transfection of different mutant KRAS oncogenes (e.g., KRAS G12C, KRAS G12D, KRAS G12V)[1].
|
| In Vivo |
BI-2493(90 mg/kg; gavage) attenuats tumour growth in mice bearing KRAS G12C, G12D, G12V and A146V mutant models, without causing apparent toxicity to the mice[1].
|
| References |
1. Kim D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023 Jul;619(7968):160-166.
|
